Borregales Leonardo D, Kim Dae Y, Staller Angie L, Qiao Wei, Thomas Arun Z, Adibi Mehrad, Tamboli Pheroze, Sircar Kanishka, Jonasch Eric, Tannir Nizar M, Matin Surena F, Wood Christopher G, Karam Jose A
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Urol Oncol. 2016 May;34(5):237.e19-26. doi: 10.1016/j.urolonc.2015.11.020. Epub 2015 Dec 18.
To study the natural history, prognosticators, and outcomes in patients with renal cell carcinoma (RCC) with extension of tumor beyond Gerota׳s fascia or invading contiguously into the adrenal gland (pT4) or both.
From 1992 to 2012, we identified 61 patients who underwent radical nephrectomy and were found to have pT4 disease. Clinicopathologic variables were queried using univariate analysis to identify relevant prognostic variables. Cox proportional hazards model was used for multivariate analysis of predictors of cancer-specific survival. Survival plots were estimated using Kaplan-Meier method and survival analysis using log-rank test.
Median age was 56 years (interquartile range: 49-64) and 49 (81.7%) patients had Eastern Cooperative Oncology Group Performance Status 0 or 1. At diagnosis, 22 (36.1%) patients showed nonmetastatic and 39 (63.9%) patients showed metastatic RCC. Overall, 49 (80.3%) patients had clear cell RCC, 24 (39.3%) patients had sarcomatoid features, and 39 (69.6%) patients had Fuhrman grade 3 to 4. There were 26 (42.6%) patients with pN0, 16 (26.2%) patients with pN1, and 19 (31.1%) patients with pNx. Median cancer-specific survival was 37 months for patients with nonmetastatic and 8 months for patients with metastatic RCC. On multivariate analysis, preoperative lactate dehydrogenase and alkaline phosphatase, M stage, pN stage, and sarcomatoid dedifferentiation were significantly associated with survival.
Survival in patients with pT4 remains poor. The pT4 disease is associated with a locally and regionally invasive biology that requires specific attention and warrants careful study. Understanding the drivers of this unique phenotype would generate therapeutic interventions that can change the behavior of these uniquely aggressive tumors.
研究肿瘤超出肾周筋膜或连续侵犯肾上腺(pT4)或两者皆有的肾细胞癌(RCC)患者的自然病程、预后因素及结局。
1992年至2012年期间,我们确定了61例行根治性肾切除术且被发现患有pT4疾病的患者。采用单因素分析查询临床病理变量,以确定相关的预后变量。使用Cox比例风险模型对癌症特异性生存的预测因素进行多因素分析。采用Kaplan-Meier方法估计生存曲线,并使用对数秩检验进行生存分析。
中位年龄为56岁(四分位间距:49 - 64岁),49例(81.7%)患者东部肿瘤协作组体能状态为0或1。诊断时,22例(36.1%)患者表现为非转移性,39例(63.9%)患者表现为转移性RCC。总体而言,49例(80.3%)患者为透明细胞RCC,24例(39.3%)患者具有肉瘤样特征,39例(69.6%)患者Fuhrman分级为3至4级。26例(42.6%)患者为pN0,16例(26.2%)患者为pN1,19例(31.1%)患者为pNx。非转移性患者的中位癌症特异性生存时间为37个月,转移性RCC患者为8个月。多因素分析显示,术前乳酸脱氢酶和碱性磷酸酶、M分期、pN分期以及肉瘤样去分化与生存显著相关。
pT4患者的生存情况仍然较差。pT4疾病与局部和区域侵袭性生物学行为相关,需要特别关注并进行深入研究。了解这种独特表型的驱动因素将产生能够改变这些极具侵袭性肿瘤行为的治疗干预措施。